NxThera has raised $14.6 million in a new round of debt financing, according to an SEC filing posted this week.
The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the 1st sale noted on Jan. 13.
NxThera is looking to raise an additional $809,831 in the round, and noted on the SEC filing that the amount sold does not include foreign purchasers. The company has not yet stated how it plans to spend funds raised in the round.
Backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, Maple Grove, Minn.-based NxThera said.
NxThera won CE Mark approval in the European Union in August 2013 and added FDA approval 2 years later for the Rezūm device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.